| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.005 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.005 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |